Hyper-IgD Syndrome care technology platforms are the digital infrastructure underpinning modern management of Hyper-IgD Syndrome (HIDS) — a rare autosomal recessive autoinflammatory periodic fever syndrome caused by biallelic hypomorphic loss-of-function mutations in MVK encoding mevalonate kinase, the second enzyme of the mevalonate-cholesterol biosynthetic pathway that phosphorylates mevalonate to mevalonate-5-phosphate in the cytoplasm, a step that is essential for the downstream production of isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP), which serve as the five-carbon building blocks for all isoprenoid compounds including geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP), squalene, cholesterol, dolichol, ubiquinone, heme A, and the protein prenylation substrates that geranylgeranylate small GTPases including Rho family members Rac1, Cdc42, and RhoA; in HIDS, hypomorphic MVK mutations reduce mevalonate kinase activity to 1–8% of normal rather than the near-complete enzyme absence seen in the severe allelic variant mevalonic aciduria (MVA), causing episodic mevalonic acid accumulation during fever-triggered metabolic stress, depletion of isoprenoid intermediates — particularly GGPP — impairing Rac1 and Cdc42 geranylgeranylation and membrane targeting, and activating the NLRP3 inflammasome through impaired prenylation-dependent negative regulation, resulting in excessive caspase-1 activation and IL-1β and IL-18 overproduction that drives the inflammatory fever attack; the HIDS fever attack is a stereotyped inflammatory episode lasting 3–7 days, triggered by vaccinations, minor infections, physical trauma, surgery, emotional stress, or sometimes spontaneously — integrating fever attack diary platforms, trigger documentation systems, anti-inflammatory therapy management dashboards, vaccination scheduling tools, growth and development monitoring platforms, laboratory marker tracking systems, quality-of-life assessment tools, and biologics management platforms that enable immunologists, pediatricians, and rheumatologists to detect fever attack escalation patterns, vaccination-triggered attack management needs, anti-inflammatory therapy inadequacy, and the rare severe spectrum MVA complications before they produce preventable prolonged inflammatory disability, amyloidosis, or the medical and developmental impact events that define uncontrolled periodic fever in inadequately monitored HIDS patients. When an HIDS care platform is unavailable or degraded, immunologists cannot access the fever attack diary records, trigger pattern analyses, anti-inflammatory therapy response data, laboratory inflammatory marker trajectories, vaccination scheduling records, quality-of-life tracking data, and biologic therapy management information that guide treatment decisions across the recurrent episodic fever, systemic inflammation, gastrointestinal manifestations, lymphadenopathy, and amyloidosis risk of HIDS and MVK Deficiency care, treatment coordination fails, and the longitudinal attack monitoring that distinguishes well-controlled HIDS from escalating attack frequency, inadequate therapy, and emerging amyloidosis risk collapses. Hyper-IgD Syndrome — caused by biallelic hypomorphic mutations in MVK (most commonly V377I in European patients, producing 1–8% residual mevalonate kinase activity that is sufficient for basal isoprenoid synthesis during metabolic homeostasis but becomes limiting during fever-driven metabolic acceleration when mevalonate kinase demand increases, producing transient mevalonic acid accumulation and GGPP depletion that impairs Rho GTPase geranylgeranylation, disrupts caveolin-1 membrane scaffolding and lipid raft organization, activates Pyrin and NLRP3 inflammasome assembly, and drives excess caspase-1 activation with IL-1β and IL-18 maturation and secretion; the fever attack is clinically characterized by high fever (≥38.5°C) lasting 3–7 days, accompanied by cervical lymphadenopathy (a hallmark finding), abdominal pain, vomiting, diarrhea, headache, arthralgia, arthritis, oral aphthous ulcers, skin lesions including maculopapular and petechial rashes, and hepatosplenomegaly; laboratory findings during attacks include markedly elevated ESR, CRP, white blood cell count, serum amyloid A, and urinary mevalonic acid; elevated serum IgD >100 IU/mL is the eponymous biomarker though it is present in only ~80% of genetically confirmed HIDS patients and is not specific; MVA represents the severe allelic extreme with near-complete MVK absence, severe mevalonic aciduria detectable by urine organic acid analysis, psychomotor retardation, cerebellar ataxia, cataracts, dysmorphic features, recurrent crises with severe illness and early death, and a clinical presentation entirely distinct from HIDS) — produces a clinical syndrome that begins typically in the first year of life, impairs quality of life through recurrent multiday inflammatory attacks occurring 4–12 times per year, may cause growth impairment, school absence, and developmental disruption in pediatric patients, and carries amyloidosis risk from chronic elevation of serum amyloid A during repeated inflammatory attacks, requiring lifelong monitoring of attack frequency and severity, inflammatory biomarker trajectories during attacks and between attacks, anti-inflammatory therapy adequacy, biologic therapy response, vaccination schedule coordination, and quality-of-life impact. The platforms that track fever attack diaries, serum amyloid A trajectories, biologic therapy adherence, vaccination scheduling, and quality-of-life trajectories must remain continuously available — because missed attack escalation alerts, delayed biologic therapy optimization, vaccination-triggered attack prevention failures, and absent amyloidosis surveillance lead to preventable uncontrolled inflammatory disease, progressive amyloidosis, and the medical and developmental morbidity that define inadequately monitored HIDS.
This guide covers what Hyper-IgD Syndrome care technology platforms need to monitor, why continuous availability matters across the spectrum of recurrent inflammatory fever attacks, systemic autoinflammatory manifestations, amyloidosis risk, biologic therapy management, and quality-of-life impact, and how to build a monitoring strategy that protects fever attack surveillance, serum amyloid A tracking, biologic therapy management, vaccination coordination, and the multi-specialty risk management workflows that HIDS care requires.
Why HIDS Care Tech Platforms Cannot Afford Downtime
HIDS management is built on four pillars: documenting fever attack frequency, severity, duration, triggers, and associated manifestations through systematic fever attack diary platforms that capture the longitudinal disease trajectory needed to guide anti-inflammatory therapy escalation and biologic therapy initiation decisions; managing anti-inflammatory and biologic therapy — NSAIDs and corticosteroids as first-line attack-aborting therapy, colchicine for attack frequency reduction in some patients, anakinra (IL-1 receptor antagonist) or canakinumab (anti-IL-1β monoclonal antibody) as biologic therapies targeting the IL-1β overproduction central to HIDS pathogenesis for patients with frequent or severe attacks — with continuous monitoring of therapy adherence, attack frequency response, and adverse effects; conducting amyloidosis surveillance through periodic serum amyloid A level monitoring between attacks, urine protein and urinalysis surveillance for early nephropathy from AA amyloidosis, and renal function tracking in patients with high attack burdens; and coordinating vaccination management recognizing that vaccinations are major HIDS attack triggers while maintaining the immune protection essential for HIDS patients whose mevalonate pathway impairment does not directly cause immunodeficiency. The platforms that support HIDS programs must remain continuously available — because an unmonitored patient whose anakinra injections were missed during a pharmacy adherence monitoring platform failure, or whose serum amyloid A had been persistently elevated indicating amyloidosis risk during a laboratory monitoring platform outage, represents a preventable disease progression risk that timely digital monitoring could have detected and prompted intervention.
Fever attack frequency and severity monitoring is the primary disease control surveillance target. The recurrent fever attacks of HIDS — driven by episodic NLRP3 and Pyrin inflammasome activation from GGPP depletion-triggered Rho GTPase impairment during metabolic stress — are the dominant source of morbidity in HIDS through pain, disability, school and work absence, hospitalization, and quality-of-life impairment; attack frequency is the primary outcome measure that guides biologic therapy initiation (typically ≥6 attacks/year or attacks severely impairing quality of life), therapy escalation, and disease control assessment; digital monitoring platforms that integrate daily fever diary submissions, attack severity scoring, attack duration tracking, trigger documentation (vaccination, infection, stress, trauma), associated symptom tracking (lymphadenopathy, abdominal symptoms, joint involvement, skin lesions), attack frequency trend analysis, and biologic therapy response assessment provide the fever attack surveillance infrastructure central to HIDS disease management.
Amyloidosis surveillance prevents the most serious long-term HIDS complication. Repeated inflammatory attacks in HIDS elevate serum amyloid A (SAA) as an acute-phase reactant; chronically elevated inter-attack SAA levels cause AA amyloidosis — fibril deposition of serum amyloid A protein in the kidney, liver, spleen, and gut causing progressive nephropathy, nephrotic syndrome, and organ failure; while amyloidosis is less frequent in HIDS than in TRAPS or FMF, its occurrence is determined by cumulative inflammatory burden; persistent inter-attack SAA elevation is the primary amyloidosis risk biomarker; digital monitoring platforms that track serial SAA levels, flag persistently elevated inter-attack SAA, coordinate renal function surveillance, and generate amyloidosis screening escalation alerts provide the long-term HIDS complication surveillance that prevents progressive nephropathy from undetected chronic inflammation.
Biologic therapy management is the cornerstone of severe HIDS disease control. Anakinra and canakinumab target the IL-1β overproduction that is the proximate driver of HIDS fever attacks; IL-1β blockade substantially reduces attack frequency and severity in most HIDS patients; biologic therapy requires adherence monitoring, injection technique and tolerability tracking, adverse effect surveillance (anakinra injection site reactions, infection susceptibility from IL-1 blockade, neutropenia monitoring), therapy response assessment through attack frequency tracking after biologic initiation, and dose optimization coordination; digital monitoring platforms that integrate biologic injection adherence tracking, adverse effect diary integration, attack frequency response analysis, CBC and inflammatory marker monitoring, and generate inadequate biologic response escalation alerts provide the biologic therapy management infrastructure for severe HIDS.
What to Monitor on an HIDS Care Tech Platform
Fever Attack Diary and Disease Activity Monitoring Platform
The fever attack surveillance and disease activity tracking service — integrating daily fever diary submission tracking with temperature recording (threshold ≥38.5°C), attack onset and resolution date documentation, attack severity scoring, associated symptom documentation (cervical lymphadenopathy palpability and size, abdominal pain severity, vomiting frequency, diarrhea, arthralgia joint mapping, oral aphthae count, skin lesion description and photography), trigger documentation (vaccination, infection, stress, physical trauma), attack frequency rolling calculations with threshold alerts for escalating attack burden, attack duration tracking with prolonged attack alerts, hospitalization tracking, emergency room visit logging, and missed school/work day tracking — is the highest-priority disease monitoring target. Check at a 1-minute interval with immediate escalation. Fever attack frequency is the primary disease control outcome measure and biologic therapy escalation trigger; real-time attack documentation enables timely therapy optimization; attack diary platform failures prevent the longitudinal disease tracking that guides HIDS management.
Biologic Therapy Management and Adverse Effect Platform
Monitor the biologic therapy management service — including anakinra injection adherence tracking with daily injection logging, canakinumab infusion scheduling and administration documentation, injection site reaction severity diary, CBC monitoring for anakinra-associated neutropenia with threshold alerts, infection surveillance during IL-1 blockade, biologic response assessment (post-biologic attack frequency vs pre-biologic baseline), biologic dose escalation and switch candidacy assessment, specialty pharmacy refill monitoring, prior authorization renewal tracking, simvastatin and other statin therapy coordination (occasionally used to reduce GGPP depletion), and colchicine adherence monitoring — at a 1-minute interval. Biologic therapy with anakinra or canakinumab is the cornerstone of severe HIDS management; adherence gaps allow disease breakthrough; neutropenia from anakinra requires CBC monitoring; biologic response adequacy assessment guides escalation decisions.
Serum Amyloid A and Amyloidosis Surveillance Platform
Monitor the serum amyloid A surveillance and amyloidosis screening service — including serial inter-attack serum amyloid A level trajectory monitoring, persistently elevated SAA threshold alert generation, serum albumin and protein monitoring for nephrotic syndrome, urinalysis with urine protein quantification (24-hour urine protein or spot urine protein:creatinine ratio), renal function monitoring (creatinine, eGFR, cystatin C) with declining renal function threshold alerts, nephrology consultation scheduling for proteinuria or renal function decline, abdominal fat pad biopsy or rectal biopsy coordination for amyloid diagnosis confirmation, and hepatic and splenic amyloid involvement assessment coordination — at a 2-minute interval. AA amyloidosis is the most serious long-term complication of uncontrolled HIDS; persistent inter-attack SAA elevation drives cumulative amyloid deposition; early detection of rising proteinuria enables nephrology intervention before nephropathy is established.
Inflammatory Biomarker and Laboratory Monitoring Platform
Monitor the inflammatory laboratory surveillance service — including serial CRP, ESR, ferritin, and white blood cell count tracking during and between attacks, serum IgD level monitoring (though insensitive), urine mevalonic acid quantification during attacks confirming MVK Deficiency biochemical signature, urinary organic acid analysis coordination, serum amyloid A trend analysis with persistent elevation alerts, CBC with differential for leukocytosis during attacks and neutropenia during biologic therapy, liver function tests for hepatitis from recurrent inflammation or azathioprine if used, and genetic testing result integration for newly diagnosed family members — at a 2-minute interval. Laboratory biomarkers quantify inflammatory burden during and between attacks; mevalonic aciduria during attacks confirms MVK Deficiency biochemistry; persistent inter-attack CRP and SAA elevation guides amyloidosis risk stratification and biologic therapy escalation decisions.
Vaccination Scheduling and Trigger Management Platform
Monitor the vaccination coordination and trigger management service — including vaccination schedule tracking with recognition of vaccination as a major HIDS attack trigger, pre-vaccination anakinra prophylaxis protocol coordination, post-vaccination attack monitoring with enhanced diary alerting, attack severity documentation following specific vaccines, deferred vaccination scheduling for patients with recent attacks, vaccination completeness monitoring given that HIDS patients need full immunization schedules despite trigger risk, influenza and COVID-19 vaccination priority tracking, and pre-vaccination corticosteroid or NSAIDs prophylaxis protocol access — at a 2-minute interval. Vaccinations are among the most consistent and potent HIDS attack triggers; vaccination scheduling requires coordination with anakinra pre-treatment to blunt the attack response; vaccination deferral during recent attacks prevents compounding triggers; platform failures interrupt the vaccination trigger management that reduces preventable post-vaccination attack severity.
Quality of Life and Growth Monitoring Platform
Monitor the quality of life and developmental surveillance service — including validated quality-of-life instrument tracking (SF-36, PedsQL for pediatric patients, disease-specific HIDS quality-of-life tools), school attendance and missed school day logging, pain diary integration, sleep quality assessment, growth percentile tracking for pediatric HIDS patients, developmental milestone assessment for pediatric patients, psychological well-being scoring with depression and anxiety screening, work productivity assessment for adult patients, disease impact on daily activities scoring, patient-reported outcome measure integration, and social support and coping resource referral coordination — at a 2-minute interval. HIDS significantly impairs quality of life through recurrent multiday inflammatory attacks; growth impairment from chronic inflammation and recurrent illness in pediatric patients requires monitoring; psychological burden of a lifelong periodic fever disorder requires mental health surveillance; quality-of-life trajectory tracking provides outcome evidence for biologic therapy justification.
Telemedicine and HIDS Multidisciplinary Coordination Platform
Monitor the telemedicine session API, immunology program nurse coordinator messaging, rheumatology consultation scheduling, pediatric rheumatology or pediatric immunology coordination for pediatric HIDS patients, nephrology consultation coordination for amyloidosis surveillance, genetics counseling scheduling, adult transition care coordination, and remote laboratory result transmission at a 2-minute interval. HIDS requires continuous coordination across immunology, rheumatology, nephrology, and genetics; platform failures interrupt the multidisciplinary consultation that manages HIDS's overlapping inflammatory, amyloidosis risk, biologic therapy, and quality-of-life domains.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. HIDS patients presenting with fever attacks, abdominal pain, hospitalization, or infection during biologic therapy require rapid provider access to their current biologic therapy status, attack frequency history, amyloidosis surveillance results, inflammatory biomarker trajectories, and emergency management protocols.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock immunologists, rheumatologists, and HIDS care coordinators out of fever attack diaries, biologic therapy management platforms, amyloidosis surveillance dashboards, inflammatory marker tracking systems, and vaccination scheduling platforms simultaneously.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for HIDS Care Tech Platforms
Immediate clinical escalation (24/7): Fever attack diary and disease activity monitoring, biologic therapy management and adverse effect monitoring, authentication service. These affect real-time attack severity assessment, biologic therapy adherence and adverse effect detection, and emergency response access that cannot tolerate delayed detection.
Immediate clinical operations escalation: Serum amyloid A and amyloidosis surveillance, inflammatory biomarker and laboratory monitoring. Failures here affect persistent SAA elevation detection and renal function surveillance that protect against amyloidosis progression.
High-priority immediate escalation: Vaccination scheduling and trigger management, quality of life and growth monitoring, telemedicine and HIDS multidisciplinary coordination. Access failures interrupt vaccination trigger management, developmental surveillance, and multi-specialty consultation.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
Fever attack diary and biologic therapy management require 24/7 alerting because HIDS attacks begin acutely and evolve over days — real-time attack documentation enables same-day anakinra initiation decisions; biologic adherence gap detection overnight prevents next-day attack breakthrough; amyloidosis surveillance platforms require immediate alerting because persistent SAA elevation trends require prompt biologic therapy escalation before irreversible amyloid accumulation occurs.
Status Page as a Clinical Safety Signal
Immunology and rheumatology program nurses and on-call coordinators managing after-hours contacts from HIDS patients reporting fever attack onset, severe abdominal pain, or injection site reactions during anakinra therapy need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems — and to initiate phone-based fever attack management guidance, anakinra dosing authorization, corticosteroid bridge prescription, and hospital routing immediately when the digital platform is confirmed unavailable.
For HIDS programs coordinating fever attack diary monitoring, biologic therapy management, amyloidosis surveillance, vaccination trigger coordination, quality-of-life tracking, and inflammatory biomarker trending across geographically dispersed patients with recurrent inflammatory fever requiring ongoing specialist oversight — a status page enables rapid identification of platform failures and activation of manual emergency protocols. Publish the status page URL in care coordinator workstations, on-call immunology and rheumatology systems, emergency department clinical systems, and patient family fever attack management protocol documents.
The Business Case: Attack Control, Amyloidosis Prevention, and HIDS Program Quality
HIDS specialty programs face significant cost exposure from preventable uncontrolled inflammatory disease in patients whose biologic therapy adherence monitoring lapsed during platform failures allowing attack breakthrough from anakinra gaps, amyloidosis development in patients whose persistent inter-attack serum amyloid A elevation went undetected during SAA monitoring platform outages allowing progressive renal amyloid deposition, severe post-vaccination fever attacks that could have been attenuated by pre-vaccination anakinra prophylaxis if vaccination scheduling platforms had been available to coordinate the pre-treatment protocol, and quality-of-life deterioration in pediatric HIDS patients from inadequate attack frequency monitoring that delayed biologic therapy escalation. Platform reliability that supports continuous attack diary monitoring, biologic therapy adherence tracking, serum amyloid A surveillance, vaccination trigger management, and quality-of-life tracking is upstream of the most preventable adverse long-term outcomes in MVK Deficiency.
HIDS program quality metrics increasingly include attack frequency per year on therapy, proportion of patients meeting biologic therapy response criteria, inter-attack serum amyloid A normalization rates, urine protein surveillance completion rates, biologic therapy adherence rates, and quality-of-life score improvement after biologic therapy initiation. Platform reliability is a direct input to outcome quality — programs whose monitoring platforms frequently fail will show higher attack rates from biologic adherence gaps, worse amyloidosis surveillance from SAA monitoring failures, and delayed biologic therapy escalation from insufficient attack frequency documentation during platform outages.
External monitoring from Vigilmon provides the documented, independent availability record that HIDS program directors can present to hospital administration and payer medical directors as evidence that the program's digital infrastructure supports the level of continuous fever attack surveillance, biologic therapy management, amyloidosis monitoring, vaccination trigger coordination, and quality-of-life tracking that MVK Deficiency's lifelong recurrent autoinflammatory disease requires.
Vigilmon Setup for HIDS Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Fever attack diary and disease activity monitoring | 1 min | PagerDuty (immediate, 24/7) | | Biologic therapy management and adverse effect monitoring | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Serum amyloid A and amyloidosis surveillance | 2 min | PagerDuty (immediate) | | Inflammatory biomarker and laboratory monitoring | 2 min | PagerDuty + Slack (immediate) | | Vaccination scheduling and trigger management | 2 min | PagerDuty + Slack (immediate) | | Quality of life and growth monitoring | 2 min | PagerDuty + Slack (immediate) | | Telemedicine and HIDS coordinator | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the fever attack diary and disease activity monitoring platform at a 1-minute interval with 24/7 PagerDuty alerting
- Add biologic therapy management and adverse effect monitoring at a 1-minute interval with immediate 24/7 escalation
- Add serum amyloid A and amyloidosis surveillance at a 2-minute interval with immediate alerting
- Add inflammatory biomarker and laboratory monitoring with immediate alerting
- Add vaccination scheduling and trigger management with immediate alerting
- Add quality of life and growth monitoring with immediate alerting
- Add telemedicine and coordinator platform monitoring with immediate alerting
- Add authentication and EHR synchronization
- Enable SSL monitoring across all patient-facing and integration domains
- Publish the automatic status page URL in care coordinator workstations, on-call immunology and rheumatology systems, emergency department clinical systems, and patient family fever attack management protocol documents
Conclusion
HIDS care tech platforms hold the clinical surveillance infrastructure that makes recurrent NLRP3 and Pyrin inflammasome-driven fever attacks manageable across their inflammatory, amyloidosis risk, biologic therapy, and quality-of-life dimensions — fever attack diary platforms, biologic therapy management dashboards, serum amyloid A monitoring systems, inflammatory biomarker tracking tools, vaccination trigger management platforms, quality-of-life assessment systems, and multidisciplinary coordination tools that cannot undo the preventable uncontrolled inflammatory disease, amyloidosis progression, biologic therapy adherence failures, and developmental morbidity accumulated during periods of unmonitored anakinra adherence, absent SAA elevation alerts, delayed biologic therapy escalation from insufficient attack documentation, and inaccessible vaccination trigger management protocols. Their availability is a prerequisite for fever attack frequency surveillance, biologic therapy adherence monitoring, amyloidosis risk detection, inflammatory biomarker trending, vaccination trigger coordination, growth and developmental outcome tracking, and the specialist access that patients with HIDS depend on throughout an illness that requires continuous attack diary documentation, regular SAA and renal surveillance, ongoing biologic therapy management, vaccination schedule coordination, and multidisciplinary oversight to prevent the clinical outcomes — progressive amyloidosis from unmonitored persistent SAA elevation, biologic therapy breakthrough from adherence monitoring failure, severe post-vaccination attacks from absent trigger management protocols, developmental impairment from inadequately treated high attack burden — that define preventable morbidity in inadequately monitored Hyper-IgD Syndrome.
External monitoring from Vigilmon provides the independent, outside-in availability view that HIDS program directors and health system IT teams need to catch failures before they affect fever attack monitoring or biologic therapy management — with the documented incident record that accreditation bodies and payer audit teams accept as evidence of operational maturity.
Start monitoring your Hyper-IgD Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #HyperIgD #HIDS #MVKdeficiency #mevalonatekinase #autoinflammatory #periodicfever #NLRP3 #IL1beta #anakinra #canakinumab #amyloidosis #serumAmyloidA #isoprenoid #GGPP #RhoGTPase #feverattack #biologic #rheumatology #immunology #pediatricRheumatology #healthtech #uptime #clinicaldocumentation #sre